| 1998年 |
MicroPort® was founded in 1998 in a small office in ZJ Hi-Tech Park in Shanghai, by a group of dedicated individuals who shared the belief that advancements in medical technology could transform patients’ lives. |
| 1998-05-15 |
Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai. |
| 1999年 |
PTCA balloon dilatation catheter received SFDA approval, very first sale made. |
| 2000年 |
Mustang™ bare metal stent received SFDA approval. |
| 2002年 |
Received major funding from National Development and Reform Commission. |
| 2003年 |
Officially entered Japan market with PTCA Balloon dilatation catheters. |
| 2004年 |
Firebird™ drug eluting stent system received SFDA approval. |
| 2004年 |
Mustang™ coronary stent system received CE mark. |
| 2005年 |
Aegis Bifurcated Stent-Graft System was named National key new product. |
| 2005年 |
Annual sales exceeded 100 million RMB. |
| 2006年 |
Hercule® Thoracic Stent-Graft System received SFDA approval. |
| 2006年 |
Coronary drug eluting stent implants reached over 100,000 units. |
| 2007年 |
Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award. |
| 2008年 |
Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented. |
| 2008年 |
Began experimental implementation of "Vertical Integration & Horizontal Connection" management model. |
| 2009年 |
Firebird2™ coronary drug-eluting stent system received registration approval from SFDA. |
| 2009年 |
Shanghai MicroPort Orthopedics Co., Ltd. was established. |
| 2010年 |
MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK). |
| 2010年 |
Annual sales exceeded 100 million USD. |
| 2010年 |
Shanghai MicroPort EP MedTech Co., Ltd. was established. |
| 2011年 |
MicroPort Medical (Jiaxing) Co., Ltd. was established. |
| 2011年 |
Undertook national R&D projects accumulating to more than 100 million RMB. |
| 2011年 |
Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd. |
| 2012年 |
Initiated “10+5” Operating Model. |
| 2012年 |
Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established. |
| 2012年 |
Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd. |
| 2013年 |
MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA. |
| 2013年 |
Globalization Strategy Implemented. |
| 2014年 |
Firehawk® rapamycin target eluting coronary stent system received CFDA approval. |
| 2014年 |
WILLIS® clinical application project won State Science and Technology Advancement Award. |
| 2014年 |
Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business. |
| 2014年 |
Acquired drug eluting stent related assets and intellectual properties from Cordis. |
| 2014年 |
Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park. |
| 2014年 |
Annual sales exceeded 2 billion RMB. |
| 2015年 |
MicroPort® Innovation Platform won State Science and Technology Advancement Award. |
| 2015年 |
Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark. |
| 2015年 |
EVOLUTION® medial-pivot knee system received CFDA approval. |
| 2015年 |
MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line. |
| 2015年 |
MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone. |
| 2015年 |
MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established. |
| 2015年 |
Founded in 2015, MicroPort |
| 2016年 |
New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award. |
| 2017年 |
Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash. |
| 2017年 |
AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award. |
| 2017年 |
Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval. |
| 2017年 |
The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0. |
| 2017年 |
Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study. |
| 2017年 |
Firesorb® pivotal study FUTURE II trial completed first enrollment. |
| 2017年 |
MicroPort® CardioFlow brought in strategic investors. |
| 2017年 |
MicroPort® EP quoted on NEEQ. |
| 2017年 |
MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors. |
| 2017年 |
MicroPort® Jiaxing park established. |
| 2017年 |
Acquired Brazil distributors to implement localized management on the Brazil market. |
| 2018年 |
Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet. |
| 2018年 |
Tubridge® Vascular Reconstruction Device was launched. |
| 2018年 |
Firehawk® and Firebird2® gained regulatory approval in Taiwan. |
| 2018年 |
First implantation of Rega® Family Implantable Pacemakers. |
| 2018年 |
Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively. |
| 2018年 |
MicroPort® CRM global headquarter was established in Clamart, France. |
| 2018年 |
MicroPort Orthopedics (Suzhou) Co., Ltd. was established. |
| 2018年 |
Every 12 seconds, a MicroPort® product was used across the world. |
| 2019年 |
SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China. |
| 2019年 |
MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System. |
| 2019年 |
The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be published in the Journal of the American College of Cardiology (JACC). |
| 2019年 |
Every 6 seconds, a MicroPort® product was used across the world. |
| 2020年 |
The MicroPort Group and its associated companies introduced external financing of over US$1 billion accumulatively and widely recognized by the capital market. |
| 2021年 |
MicroPort® CardioFlow Medtech was listed on the Main Board of the Hong Kong Stock Exchange |
| 2021年 |
MicroPort® MedBot® was listed on the Main Board of the Hong Kong Stock Exchange |
| 2021年 |
MicroPort® CRM introduced the Alizea™ and Borea™ pacemakers equipped with Bluetooth technology and the SmartView Connect™ home monitor in Europe. |
| 2021年 |
MicroPort® CRM Navigo™ left ventricular pacing leads received CE mark approval in Europe |
| 2021年 |
MicroPort NeuroTech™ U-track Intracranial Support Catheter System became commercially available in the market |
| 2021年 |
EverPace Disposable Cardiac Mapping Leads became commercially available in the market |
| 2021年 |
Firefighter™ and Foxtrot® Pro PTCA Balloon Dilatation Catheter approved for marketing in Pakistan and Bosnia and Herzegovina |
| 2021年 |
HorizonMedical™ Daylily® Embryo Transfer Catheter approved for marketing in Thailand |
| 2021年 |
Four products including Firehawk® Stent and Firefighter™ PTCA Balloon Dilatation Catheter received registration and marketing approval in Saudi Arabia |
| 2021年 |
Firefighter™ NC received registration approval in Taiwan. |
| 2022年 |
MicroPort NeuroTech was listed on the Main Board of the Hong Kong Stock Exchange |
| 2022年 |
MicroPort MedBot Skywalker™ Orthopedic Surgical Robot received NMPA approval in China, FDA 510(k) approval in the US and CE mark approval in Europe |
| 2022年 |
MicroPort NeuroTech Diveer® Intracranial Balloon Catheter, Neurohawk® Stent Thrombectomy Device, X-track® Intracranial Distal Access Catheter, and NUMEN Silk® 3D Electronically Detachable Coil received NMPA approvals in China |
| 2022年 |
MicroPort MedBot Toumai® Laparoscopic Surgical Robot received NMPA approval in China and won several awards |
| 2022年 |
MicroPort® CRM Invicta™ Defibrillation leads received CE mark approval in Europe |
| 2022年 |
MicroPort Endovascular Talos® Thoracic Stent Graft System received NMPA approval in China |
| 2022年 |
MicroPort Urocare Single-use Flexible Digital Ureteroscope received the NMPA approval in China |
| 2022年 |
MicroPort Argus™ intravascular OCT system received NMPA approval in China |
| 2022年 |
MicroPort® inaugurated a training Center in Brazil |
| 2024年 |
MicroPort® obtained 4 FDA approvals, including: MicroPort® Orthopedics EVOLUTION® Tibial Cones |
| 2024年 |
58 products obtained NMPA's approval in China, including: MicroPort® Orthopedics Evolution® CCK Knee Revision System |
| 2024年 |
And 6 products entered NMPA's "Green Path", including: MicroPort® Orthopedics Wrist Arthroplasty System |
| 2025年 |
MicroPort® CardioFlow completed a strategic merger with MicroPort® CRM, building a comprehensive heart failure management solution spanning all etiologies, stages, and treatment pathways. |
| 2025年 |
MicroPort® obtained 7 FDA approvals, including: MicroPort® Orthopedics NEXUS® Femoral Stem. |
| 2025年 |
MicroPort® obtained 23 CE approvals, including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft System (custom certification). |
| 2025年 |
MicroPort® obtained 23 CE approvals, including: MicroPort EverPace™ IceMagic™ Cryoablation System. |
| 2025年 |
MicroPort® obtained 23 CE approvals, including: MicroPort® CRM MR-Conditional Mixed Pacing System and VEGA™ M lead. |
| 2025年 |
Over 30 products received NMPA Class III medical device registration, including: MicroPort® Coronary TomaHawk® Intravascular Lithotripsy Catheter and Firelimus® Drug-Eluting Balloon, MicroPort® CardioFlow AnchorMan® Left Atrial Appendage Closure System, MicroPort® CRM TEN Series 3.0T MRI-Conditional Pacemakers, MicroPort® Endovastec™ Cratos™ Thoracic Branch Stent Graft, MicroPort EverPace™ PulseMagic™ TrueForce® PFA Catheter, MicroPort® MedBot UniPath® Surgical Navigation System and Toumai® SP Single-Port Robot, MicroPort® VisionPower YINI® Cataract Phacoemulsification System, MicroPort® MicroVasive EZ-Eye™ 5100 GI Endoscopy System, MicroPort® Dentition YairDent® Dental Implant System. |
| 2025年 |
41 products were accepted into the NMPA’s 'Green Path', including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft, MicroPort® UniFlow Streamliner™ Implantable Tibial Nerve Stimulator, MicroPort EverPace™ EasyEcho™ Intracardiac Ultrasound Catheter, MicroPort NeuroScientific StraitPass™ Disposable Hematoma Aspiration Device. |
| 2025年 |
MicroPort® CRM VEGA™ M58 Pacing Lead approved in Australia, MicroPort® CardioFlow VitaFlow Liberty® Transcatheter Aortic Valve System approved in 15 countries, including Brazil and Morocco, MicroPort® MedBot Toumai® Remote Surgery System approved in 10 countries. |
| 2025年 |
TARGET-FIRST Trial results for MicroPort® Coronary Firehawk® Stent published in The New England Journal of Medicine and presented at ESC 2025, demonstrating safety of 1-month DAPT in low-risk AMI patients with complete revascularization. |
| 2025年 |
MicroPort® Coronary surpassed 10 million stent systems shipped and implanted globally. |
| 2025年 |
MicroPort® MedBot Toumai® Surgical Robot achieved over 100 global commercial installations. |
| 2025年 |
The Toumai® system also achieved multiple robotic surgery milestones, including: The world’s first commercial remote robotic surgery. |
| 2025年 |
The Toumai® system also achieved multiple robotic surgery milestones, including: The first FDA-IDE approved remote robotic surgery. |
| 2025年 |
The Toumai® system also achieved multiple robotic surgery milestones, including: The first remote robotic surgery in Europe. |
| 2025年 |
The Toumai® system also achieved multiple robotic surgery milestones, including: The first ultra-remote 5G robotic surgery at over 4,500 meters altitude. |
| 2025年 |
The Toumai® system also achieved multiple robotic surgery milestones, including: The first low-orbit satellite remote surgery. |
| 2025-06-11 |
MicroPort® CardioFlow’s VitaFlow Liberty® Expands Global Presence with Key Milestones in Europe and Latin America |
